Liver cancer is the fifth most common cancer and the second leading cause of malignant
death in Asia, and Asia reports 72.5% of the world's cases in 2020. As the most common …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the second
leading cause of cancer-related mortality worldwide. This review is an updated version that …

Background Single-agent nivolumab showed durable responses, manageable safety, and
promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 …

METHODS In this open-label, phase III trial, patients with advanced HCC, previously
untreated with systemic therapy, were randomly assigned in a 1: 1 ratio to receive HAIC-FO …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.
Surveillance for HCC is critical for early detection and treatment, but fewer than one-quarter …

Atezolizumab plus bevacizumab (Atezo/Bev) followed by curative conversion (ABC
conversion) therapy is very effective in the treatment of unresectable, transarterial …

The focus of hepatocellular carcinoma (HCC) research for many years has been on
noninvasive diagnosis. Standardized systematic algorithms composed of combinations of …

Introduction: Several clinical trials comparing the efficacy and safety of transarterial
chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no …

Hepatocellular carcinoma (HCC) is estimated to be the third leading cause of cancer-related
mortality and is characterized by low survival rates. Nonalcoholic fatty liver disease (NAFLD) …

Advances in the surgical and systemic therapeutic landscape of hepatocellular carcinoma
have increased the complexity of patient management. A dynamic adaptation of the …